Histotype
Leukemia [AML]
| Parameter | Information |
|---|---|
| Strain | NSG |
| Implant Type | Cells |
| Implant Location | IV |
| Time to Staging | 5 days |
| Time to Evaluation Size (days) | N/A |
| Td | 2.6 days |
The above parameters are from one study. For further information on this cell line and other parameters, including different strains, vendors, implant type and location and/or standards of care, please contact us.
Tumor Line
Human
Ref #
2159
Spotlight on MV(4;11): A model of human AML (acute myeloid leukemia)
Learn more about this cell line in our scientific spotlights:
In an effort to more effectively evaluate treatments preclinically, Labcorp offers a human AML model, MV(4;11) (FUW-Luc-mCherry-puro), that has been modified to include both luciferase and mCherry reporter constructs. Through expression of luciferase, bioluminescent imaging (BLI) can be used to quantitatively measure and track in vivo disease progression in a longitudinal manner. In addition, expression of mCherry can be used ex vivo to detect presence or absence of tumor cells in the bone marrow. At Labcorp we have optimized the MV(4;11) model in female NSG mice (Jackson Labs). Our ability to track disease progression with BLI makes this model a powerful tool for investigators discovering and developing novel drugs for AML by coupling traditional pharmacology endpoints such as overall survival and body weight loss with in vivo, quantitative disease progression over time. Preclinically, BLI has become the cornerstone imaging modality in the quantification of hematologic malignancy models and is invaluable to the drug discovery process.